Cardiac safety of systemic therapy in breast cancer patients with high risk of atherosclerosis complications.

<bold>Aim: </bold>This study was designed to verify the efficacy of breast cancer treatment and its cardiac toxicity in population with significant cardiac comorbidities.<bold>Materials& Methods: </bold>Prospective observational study was conducted in 48 patients.<bold>Results: </bold>The increase and dependence of echocardiographic parameter early/late were observed on hemoglobin level in all patients, and white blood cells and cholesterol in patients with diabetic were reported. Patients undergo left ventricle diameter change on treatment.<bold>Conclusion: </bold>Use of potentially cardiotoxic chemo regimens in breast cancer patients with cardiac comorbidities, with optimized cardiac therapy accordingly can save patients from development of early myocardial dysfunction induced by chemotherapy - limiting factor to minimize the risk is optimization of lipid level, red blood cell count and platelets count. [ABSTRACT FROM AUTHOR]